In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIIBiomarker/Laboratory analysis, TreatmentActive18 and overNCINCI-2011-01981
ECOG-E1208, CDR0000657952, E1208, U10CA021115, NCT01004978

Trial Description

Summary

This randomized phase III trial is studying chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking the blood flow to the tumor. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemoembolization together with sorafenib tosylate is more effective than chemoembolization alone in treating patients with liver cancer.

Further Study Information

PRIMARY OBJECTIVE:

I. To compare Progression-Free Survival (PFS) of chemoembolization alone to sorafenib in combination with chemoembolization.

SECONDARY OBJECTIVES:

I. To compare overall survival (OS) of chemoembolization alone to sorafenib in combination with chemoembolization.

II. To evaluate extra-hepatic versus intra-hepatic patterns of failure. III. To determine the rates of toxicity related to Sorafenib in combination with chemoembolization.

TERTIARY OBJECTIVES:

I. To analyze the pharmacogenetic and pharmacokinetic properties of Sorafenib including angiogenesis, monooxygenases, polymorphisms and MDR.

II. ECOG secondary imaging objective: Site vs. Central evaluation of PFS. III. To determine the inter-reader concordance for response characterization at four and eight months by the European Association for the Study of Liver (EASL) criteria.

IV. To determine the value of objective tumor response at four and eight months by the EASL criteria to predict PFS (by RECIST) and OS.

V. To evaluate the effects of intra-hepatic vs. extra-hepatic progression on OS.

OUTLINE: This is a multicenter study. Patients are stratified according to macrovascular intrahepatic portal vein invasion (present vs absent), Child Pugh score (A vs B7), and chemoembolization method (doxorubicin-eluting bead vs conventional). Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive sorafenib tosylate orally (PO) twice daily in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo transarterial chemoembolization (TACE) comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (closed to accrual as of 10/1/2010); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising doxorubicin-eluting beads. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo PO twice daily in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in arm I.

MAINTENANCE THERAPY: After completion of chemoembolization, patients receive sorafenib tosylate or placebo as in arm I and II in the absence of disease progression or unacceptable toxicity. Patients undergo chest, abdomen, and/or pelvis CT scans or MRI at baseline, at 4 and 8 months, and every 2 months thereafter.

Blood and tissue samples may be collected at baseline and periodically during study for pharmacogenetic and pharmacokinetic studies. After completion of study therapy, patients are followed up periodically for 4 years.

Eligibility Criteria

Inclusion Criteria:

  • Diagnosis of hepatocellular carcinoma (HCC) according to 1 of the following criteria:
  • Histologically confirmed disease
  • Liver cirrhosis AND ≥ 1 solid liver lesion > 2 cm with early enhancement and delayed enhancement washout on CT scan or MRI regardless of alpha-fetoprotein levels (AFP)
  • AFP > 400 ng/mL AND ≥ 1 solid liver lesion > 2 cm regardless of specific imaging characteristics on CT scan or MRI
  • Disease must be limited to the liver
  • No clinical or radiographic evidence of extra hepatic HCC
  • Portal vein lymphadenopathy is allowed for patients with hepatitis B or C
  • Branch portal vein invasion by tumor allowed
  • No main portal vein invasion by tumor
  • Measurable disease constituting < 50% of liver parenchyma within the past 4 weeks
  • Child Pugh score of A or B7 within the past 4 weeks
  • No ascites detectable on physical evaluation
  • Not a candidate for curative resection, orthotopic liver transplantation, or radiofrequency ablation (RFA)
  • ECOG performance status 0-1
  • Life expectancy ≥ 3 months
  • Platelet count ≥ 50,000/μL
  • Total bilirubin ≤ 2.0 mg/dL
  • Alkaline phosphatase < 5 times upper limit of normal (ULN)
  • AST and ALT < 5 times ULN
  • Serum creatinine ≤ 1.5 mg/dL
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Able to swallow pills
  • No clinical signs of heart failure
  • No NYHA class III or IV heart disease
  • No evidence of bleeding diathesis or active gastrointestinal bleeding
  • No known HIV positivity
  • No other concurrent uncontrolled illness (except hepatitis B or C) including, but not limited to, any of the following:
  • Uncontrolled hypertension (i.e., optimally treated baseline BP > 150/90 mm Hg)
  • Symptomatic congestive heart failure
  • Unstable angina pectoris
  • Cardiac arrhythmia
  • Psychiatric illness and/or addictive disorder that would limit compliance with study requirements
  • No allergy to iodine or gadolinium contrast that cannot be safely controlled with premedication
  • No prior brachytherapy (e.g., yttrium-90 microspheres)
  • No prior sorafenib tosylate, chemoembolization, or systemic chemotherapy, including cytotoxic agents or molecularly targeted agents
  • Prior attempted curative liver resection allowed
  • More than 4 weeks since prior RFA
  • No concurrent cytochrome P450 enzyme-inducing drugs
  • No concurrent prophylactic G-CSF or GM-CSF

Trial Contact Information

Trial Lead Organizations/Sponsors

National Cancer Institute

John KauhPrincipal Investigator

Trial Sites

U.S.A.
Alabama
  Birmingham
 UAB Comprehensive Cancer Center
 Carla I. Falkson Ph: 205-934-0309
  Mobile
 University of South Alabama Mitchell Cancer Institute
 William R Taylor Ph: 251-665-8000
  Email: pfrancisco@usouthal.edu
Arkansas
  Little Rock
 Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
 Rangaswamy Govindarajan Ph: 501-686-8274
 Veterans Affairs Medical Center - Little Rock
 Rangaswamy Govindarajan Ph: 501-686-8274
California
  Greenbrae
 Marin Cancer Institute at Marin General Hospital
 Peter D. Eisenberg Ph: 415-925-5000
  Email: info@marinspecialtycare.com
  Los Angeles
 USC/Norris Comprehensive Cancer Center and Hospital
 Anthony Boutros El-Khoueiry Ph: 323-865-0451
  Orange
 St. Joseph Hospital Regional Cancer Center - Orange
 Tariq Mahmood Ph: 714-541-6622
  San Francisco
 San Francisco General Hospital Medical Center
 Alan Paul Venook Ph: 877-827-3222
 UCSF Helen Diller Family Comprehensive Cancer Center
 Alan Paul Venook Ph: 877-827-3222
  Stanford
 Stanford Cancer Center
 Daniel Y Sze Ph: 650-498-7061
  Email: clinicaltrials@med.stanford.edu
Colorado
  Denver
 Porter Adventist Hospital
 Keren Sturtz Ph: 888-785-6789
Connecticut
  Hartford
 Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
 Philip J. Stella Ph: 734-712-3456
  New Haven
 Yale Cancer Center
 Stacey M Stein Ph: 203-785-5702
Delaware
  Newark
 Helen F. Graham Cancer Center at Christiana Hospital
 Gregory A. Masters Ph: 302-733-6227
Florida
  Lakeland
 Lakeland Regional Cancer Center at Lakeland Regional Medical Center
 Manuel A Molina-Vega Ph: 863-904-1900
Georgia
  Atlanta
 Winship Cancer Institute of Emory University
 Natalyn N Hawk Ph: 404-778-1868
  Macon
 Medical Center of Central Georgia
 Frederick M. Schnell Ph: 478-633-1226
Hawaii
  Aiea
 Kapiolani Medical Center at Pali Momi
 Jeffrey L. Berenberg Ph: 808-586-2979
  Honolulu
 Cancer Research Center of Hawaii
 Jeffrey L. Berenberg Ph: 808-586-2979
 Hawaii Medical Center - East
 Jeffrey L. Berenberg Ph: 808-586-2979
 Kapiolani Medical Center for Women and Children
 Jeffrey L. Berenberg Ph: 808-586-2979
 OnCare Hawaii, Incorporated - Kuakini
 Jeffrey L. Berenberg Ph: 808-586-2979
 Jeffrey L. Berenberg Ph: 808-586-2979
 OnCare Hawaii, Incorporated - Lusitana
 Jeffrey L. Berenberg Ph: 808-586-2979
 Queen's Cancer Institute at Queen's Medical Center
 Jeffrey L. Berenberg Ph: 808-586-2979
  Kailua
 Castle Medical Center
 Jeffrey L. Berenberg Ph: 808-586-2979
  Lihue
 Kauai Medical Clinic
 Jeffrey L. Berenberg Ph: 808-586-2979
Idaho
  Boise
 Mountain States Tumor Institute at St. Luke's Regional Medical Center
 Paul G. Montgomery Ph: 800-845-4624
 Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
 Philip J. Stella Ph: 734-712-3456
Illinois
  Bloomington
 St. Joseph Medical Center
 Nguyet A Le-Lindqwister Ph: 800-793-2262
  Chicago
 John H. Stroger, Jr. Hospital of Cook County
 Thomas E. Lad Ph: 312-864-6000
 Robert H. Lurie Comprehensive Cancer Center at Northwestern University
 Al Bowen Benson Ph: 312-695-1301
  Email: cancer@northwestern.edu
 University of Chicago Cancer Research Center
 Daniel V Catenacci Ph: 773-834-7424
 University of Illinois Cancer Center
 Howard Ozer Ph: 312-355-3046
  Evanston
 St. Francis Hospital
 K. Joseph Philip Ph: 773-878-8200
  Galesburg
 Galesburg Clinic, PC
 Nguyet A Le-Lindqwister Ph: 800-793-2262
 Medical and Surgical Specialists, LLC
 Nguyet A Le-Lindqwister Ph: 800-793-2262
  Harvey
 Ingalls Cancer Care Center at Ingalls Memorial Hospital
 Thomas M Aquisto Ph: 708-915-4673
  Email: clinicaltrials@ingalls.org
  Hines
 Veterans Affairs Medical Center - Hines
 Abdul M. Choudhury Ph: 708-202-8387
  Hinsdale
 Hinsdale Hematology Oncology Associates
 Elyse Cheryl Schneiderman Ph: 630-654-1790
  Email: info@hhoaltd.com
  Kankakee
 Provena St. Mary's Regional Cancer Center - Kankakee
 Al Bowen Benson Ph: 312-695-1301
  Email: cancer@northwestern.edu
  La Grange
 La Grange Memorial Hospital
 Renee H. Jacobs Ph: 630-856-7526
  Libertyville
 North Shore Oncology and Hematology Associates, Limited - Libertyville
 Al Bowen Benson Ph: 312-695-1301
  Email: cancer@northwestern.edu
  Niles
 Cancer Care and Hematology Specialists of Chicagoland - Niles
 Al Bowen Benson Ph: 312-695-1301
  Email: cancer@northwestern.edu
  Normal
 Community Cancer Center
 Nguyet A Le-Lindqwister Ph: 800-793-2262
  Ottawa
 Community Hospital of Ottawa
 Nguyet A Le-Lindqwister Ph: 800-793-2262
  Pekin
 Cancer Treatment Center at Pekin Hospital
 Nguyet A Le-Lindqwister Ph: 800-793-2262
  Peoria
 CCOP - Illinois Oncology Research Association
 Nguyet A Le-Lindqwister Ph: 800-793-2262
 Illinois CancerCare - Peoria
 Nguyet A Le-Lindqwister Ph: 800-793-2262
 Methodist Medical Center of Illinois
 Nguyet A Le-Lindqwister Ph: 800-793-2262
 OSF St. Francis Medical Center
 Nguyet A Le-Lindqwister Ph: 800-793-2262
  Rockford
 Advanced Care and Treatment Medical Group, PC
 Harvey Eric Einhorn Ph: 779-696-9400
  Email: cancercare@swedishamerican.org
  Skokie
 Hematology Oncology Associates - Skokie
 Al Bowen Benson Ph: 312-695-1301
  Email: cancer@northwestern.edu
Kansas
  Hays
 Hays Medical Center
 Peter J. VanVeldhuizen Ph: 800-525-1483
  Kansas City
 Kansas City Cancer Centers - West
 Peter J. VanVeldhuizen Ph: 800-525-1483
 Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
 Peter J. VanVeldhuizen Ph: 800-525-1483
  Overland Park
 Kansas City Cancer Centers - Southwest
 Peter J. VanVeldhuizen Ph: 800-525-1483
  Pittsburg
 Mount Carmel Regional Cancer Center
 Peter J. VanVeldhuizen Ph: 800-525-1483
  Prairie Village
 CCOP - Kansas City
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
  Salina
 Tammy Walker Cancer Center at Salina Regional Health Center
 Peter J. VanVeldhuizen Ph: 800-525-1483
  Shawnee Mission
 Kansas City Cancer Center - Shawnee Mission
 Peter J. VanVeldhuizen Ph: 800-525-1483
  Topeka
 St. Francis Comprehensive Cancer Center
 Peter J. VanVeldhuizen Ph: 800-525-1483
Kentucky
  Lexington
 University of Kentucky Chandler Medical Center
 John J Rinehart Ph: 859-257-3379
Louisiana
  New Orleans
 Ochsner Cancer Institute at Ochsner Clinic Foundation
 Jyotsna Fuloria Ph: 888-562-4763
Maryland
  Baltimore
 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 Jean-Francois (Jeff) H Geschwind Ph: 410-955-8804
  Email: jhcccro@jhmi.edu
 St. Agnes Hospital Cancer Center
 Carole Miller Ph: 410-368-2910
Massachusetts
  Boston
 Tufts Medical Center Cancer Center
 Kevin P Daly Ph: 617-636-5000
  Email: ContactUsCancerCenter@TuftsMedicalCenter.org
  Burlington
 Lahey Clinic Medical Center - Burlington
 Keith Ellis Stuart Ph: 781-744-8027
Michigan
  Ann Arbor
 University of Michigan Comprehensive Cancer Center
 Paula M Novelli Ph: 800-865-1125
  Flint
 Genesys Hurley Cancer Institute
 Philip J. Stella Ph: 734-712-3456
  Kalamazoo
 West Michigan Cancer Center
 Raymond Sterling Lord Ph: 269-373-7458
  Livonia
 St. Mary Mercy Hospital
 Philip J. Stella Ph: 734-712-3456
  Saginaw
 Seton Cancer Institute at Saint Mary's - Saginaw
 Philip J. Stella Ph: 734-712-3456
  Southfield
 Providence Hospital - Southfield
 Anibal Drelichman Ph: 248-849-5337
  Email: jaswinder.grewal@stjohn.org
Minnesota
  Minneapolis
 Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Robbinsdale
 Humphrey Cancer Center at North Memorial Outpatient Center
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Saint Paul
 Regions Hospital Cancer Care Center
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
 United Hospital
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Waconia
 Ridgeview Medical Center
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
Mississippi
  Jackson
 University of Mississippi Cancer Clinic
 Louis V Puneky Ph: 601-815-6700
Missouri
  Columbia
 Veterans Affairs Medical Center - Columbia (Truman Memorial)
 Shadi M Haddadin Ph: 888-823-5923
  Email: ctsucontact@westat.com
  Kansas City
 Kansas City Cancer Centers - North
 Peter J. VanVeldhuizen Ph: 800-525-1483
 Kansas City Cancer Centers - South
 Peter J. VanVeldhuizen Ph: 800-525-1483
 Saint Luke's Hospital
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
 Truman Medical Center - Hospital Hill
 Peter J. VanVeldhuizen Ph: 800-525-1483
 Veterans Affairs Medical Center - Kansas City
 Suman Kambhampati Ph: 800-525-1483
  Lee's Summit
 Kansas City Cancer Centers - East
 Peter J. VanVeldhuizen Ph: 800-525-1483
  Saint Louis
 Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
 Benjamin R Tan Ph: 800-600-3606
  Email: info@siteman.wustl.edu
Montana
  Great Falls
 Benefis Sletten Cancer Institute
 Benjamin Thomas Marchello Ph: 800-648-6274
Nebraska
  Omaha
 Methodist Estabrook Cancer Center
 Robert M. Langdon Ph: 402-354-5144
Nevada
  Reno
 Renown Institute for Cancer at Renown Regional Medical Center
 Christos A Galanopoulos Ph: 775-982-4400
New Jersey
  Newark
 UMDNJ University Hospital
 Lillian F. Pliner Ph: 732-235-8675
New Mexico
  Albuquerque
 University of New Mexico Cancer Center
 Fa-Chyi Lee Ph: 505-272-6972
New York
  Brooklyn
 Maimonides Cancer Center at Maimonides Medical Center
 Yiwu (Jim) Huang Ph: 718-765-2500
 Veterans Affairs Medical Center - Brooklyn
 Harold S Ballard Ph: 212-263-4434
  Email: prmc.coordinator@nyumc.org
  New York
 Beth Israel Medical Center - Petrie Division
 Peter Kozuch Ph: 212-844-6286
 New York University Medical Center
 George Miller Ph: 212-263-4434
  Email: prmc.coordinator@nyumc.org
 St. Luke's - Roosevelt Hospital Center - St.Luke's Division
 Peter Kozuch Ph: 212-844-6286
 Veterans Affairs Medical Center - New York
 Harold S Ballard Ph: 212-263-4434
  Email: prmc.coordinator@nyumc.org
North Carolina
  Chapel Hill
 Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
 Cheryl A Carlson Ph: 877-668-0683
  Email: cancerclinicaltrials@med.unc.edu
  Charlotte
 Presbyterian Cancer Center at Presbyterian Hospital
 Justin P Favaro Ph: 704-384-5369
  Winston-Salem
 Wake Forest University Comprehensive Cancer Center
 Perry Shen Ph: 336-713-6771
Ohio
  Cincinnati
 University of Cincinnati
 Olugbenga Olowokure (Gbenga) Ph: 513-558-4553
  Email: uchealthnews@uc.edu
  Cleveland
 Case Comprehensive Cancer Center
 Cheng E Chee Ph: 800-641-2422
 Cleveland Clinic Taussig Cancer Center
 Anjali S Advani Ph: 866-223-8100
 MetroHealth Cancer Care Center at MetroHealth Medical Center
 Bruce J. Averbook Ph: 216-778-8526
  Email: kbauchens@metrohealth.org
  Columbus
 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
 Carl R Schmidt Ph: 866-627-7616
  Email: osu@emergingmed.com
  Sylvania
 Flower Hospital Cancer Center
 Rex B Mowat Ph: 517-265-0116
  Toledo
 St. Anne Mercy Hospital
 Rex B Mowat Ph: 517-265-0116
 University of Toledo Medical Center
 Rex B Mowat Ph: 517-265-0116
Oklahoma
  Oklahoma City
 Oklahoma University Cancer Institute
 Carla Kurkjian Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
Oregon
  Gresham
 Legacy Mount Hood Medical Center
 Ian D Schnadig Ph: 503-692-2032
  Portland
 Legacy Good Samaritan Hospital & Comprehensive Cancer Center
 Ian D Schnadig Ph: 503-692-2032
  Tualatin
 Legacy Meridian Park Hospital
 Ian D Schnadig Ph: 503-692-2032
Pennsylvania
  Danville
 Geisinger Cancer Institute at Geisinger Health
 Maged F Khalil Ph: 610-402-2273
  Philadelphia
 Albert Einstein Cancer Center
 John Leighton Ph: 215-456-3880
 Fox Chase Cancer Center - Philadelphia
 Crystal S Denlinger Ph: 215-728-4790
 Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
 Nancy Lewis Ph: 215-955-6084
South Carolina
  Anderson
 AnMed Cancer Center
 Charles E Bowers Ph: 800-486-5941
 Charles E Bowers Ph: 800-486-5941
  Charleston
 Hollings Cancer Center at Medical University of South Carolina
 Melanie B Thomas Ph: 843-792-9321
  Spartanburg
 CCOP - Upstate Carolina
 Charles E Bowers Ph: 800-486-5941
 Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
 Charles E Bowers Ph: 800-486-5941
Tennessee
  Jackson
 West Tennessee Cancer Center at Jackson-Madison County General Hospital
 Salomon Asmar Ph: 731-425-6865
Texas
  Amarillo
 Harrington Cancer Center
 Stewart Allen Sharp Ph: 806-359-4673
  Email: ryokubaitis@harringtoncc.org
Utah
  Salt Lake City
 Huntsman Cancer Institute at University of Utah
 Ryan G O'Hara Ph: 801-581-4477
  Email: clinical.trials@hci.utah.edu
Virginia
  Midlothian
 Bon Secours Cancer Institute - Virginia Breast Center
 William J Irvin Ph: 804-594-4900
  Richmond
 Bon Secours Cancer Institute at St. Mary's Hospital
 William J Irvin Ph: 804-594-4900
 Virginia Commonwealth University Massey Cancer Center
 Andrew Poklepovic Ph: 804-628-1939
Washington
  Auburn
 Auburn Regional Center for Cancer Care
 Yoshio Inoue Ph: 253-403-2394
  Burien
 Highline Medical Center Cancer Center
 Gary E Goodman Ph: 206-386-2323
  Email: patra.grevstad@swedish.org
  Centralia
 Providence Centralia Hospital
 Yoshio Inoue Ph: 253-403-2394
  Everett
 Providence Regional Cancer Partnership
 Yoshio Inoue Ph: 253-403-2394
  Federal Way
 St. Francis Hospital
 Yoshio Inoue Ph: 253-403-2394
  Olympia
 Providence St. Peter Hospital Regional Cancer Center
 Yoshio Inoue Ph: 253-403-2394
  Puyallup
 Good Samaritan Cancer Center
 Yoshio Inoue Ph: 253-403-2394
  Seattle
 CCOP - Virginia Mason Research Center
 Craig R. Nichols Ph: 503-215-6412
 Group Health Central Hospital
 Gary E Goodman Ph: 206-386-2323
  Email: patra.grevstad@swedish.org
  Tacoma
 Allenmore Hospital
 Yoshio Inoue Ph: 253-403-2394
 CCOP - Northwest
 Yoshio Inoue Ph: 253-403-2394
 Franciscan Cancer Center at St. Joseph Medical Center
 Yoshio Inoue Ph: 253-403-2394
 MultiCare Regional Cancer Center at Tacoma General Hospital
 Yoshio Inoue Ph: 253-403-2394
 St. Clare Hospital
 Yoshio Inoue Ph: 253-403-2394
  Vancouver
 Legacy Salmon Creek Medical Center
 Ian D Schnadig Ph: 503-692-2032
West Virginia
  Morgantown
 Mary Babb Randolph Cancer Center at West Virginia University Hospitals
 Brent T Steadman Ph: 304-293-2745
  Email: sfilburn@hsc.wvu.edu
Wisconsin
  Madison
 University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
 William R Schelman Ph: 877-405-6866
  Marshfield
 Marshfield Clinic - Marshfield Center
 Kristin M. Gerndt Ph: 715-389-4457

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01004978
ClinicalTrials.gov processed this data on April 10, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top